α-Synuclein Aggregation in Treatment of Parkinson's Disease
Por um escritor misterioso
Descrição
Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.
Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
Anti-Alpha-Synuclein Therapies in Parkinson's Disease - Practical Neurology
IJMS, Free Full-Text
PAP reduced α-synuclein expression and aggregation in MPTP/P-treated
Alpha Synuclein – The Science of Parkinson's
ISIS Studying the influence of salts on α-synuclein aggregation, a hallmark of Parkinson's disease
Small soluble α-synuclein aggregates are the toxic species in Parkinson's disease
IJMS, Free Full-Text
Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson's disease
Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies
Frontiers Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease
Pathological pathway of α-synuclein aggregation. Abnormal misfolded
Interactions between iron and α-synuclein pathology in Parkinson's disease - ScienceDirect
de
por adulto (o preço varia de acordo com o tamanho do grupo)
